LCIP
UTHR icon

Life Cycle Investment Partners’s United Therapeutics UTHR Stock Holding History

Life Cycle Investment Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Buy
+20,312
New +$11.4M 0.05% 145

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Life Cycle Investment Partners's UTHR Position: Q2 2026 in Review

Life Cycle Investment Partners opened a new position in United Therapeutics (UTHR) in Q2 2026: 20,312 shares worth $11M. The stake represents 0.05% of the portfolio and ranks #145 among its holdings.

874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Life Cycle Investment Partners held 20,312 shares of United Therapeutics worth $11M as of Q2 2026.
  • United Therapeutics was a new Life Cycle Investment Partners position in Q2 2026.
  • United Therapeutics made up 0.05% of Life Cycle Investment Partners's portfolio in Q2 2026, its #145 holding.
  • 874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Life Cycle Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.